Introduction {#Sec1}
============

Type 1 diabetes (T1D), which affects the insulin-producing beta cells of the pancreas, and Addison's disease (AD), which results from the destruction of the adrenal cortex, are life-threatening autoimmune conditions, leading to the absolute dependence on exogenous hormones supply. Unfortunately, in the vast majority of cases, the origin of the auto-aggressive phenomena remains obscure. It has been proposed that the autoimmune reactions are triggered in genetically predisposed subjects on encounter of some environmental factors, which may promote aberrant immune reactivity (Michels and Eisenbarth [@CR22]). There is a mounting body of evidence in support of the role of the viral infections, notably by enteroviruses, in the development of T1D. Enteroviruses present tropism for pancreatic islets and enterovirus antibodies and RNA are found in newly diagnosed T1D patients more frequently than in their healthy peers (Tauriainen et al. [@CR36]; Yeung et al. [@CR40]). The environmental influence in aetiology of AD is even less recognized. Some authors have reported its relationship with herpesvirus infections and recent experimental data corroborate that virus-induced type I and III interferons (IFNs) might initiate or enhance an ongoing autoimmune reaction (Hellesen et al. [@CR9]; Schmitt et al. [@CR29]).

Mechanisms of the non-specific immunity start to draw increasing attention in the context of autoimmune disorders (Meyers et al. [@CR21]). According to the association studies, innate immunity genes---*CIITA*, *NLRP1* and *IFIH1*---may be implicated in beta cell and adrenal cortex autoimmunity (Magitta et al. [@CR19]; Skinningsrud et al. [@CR31]; Smyth et al. [@CR32]). They belong to the pattern recognition receptors (PRRs) that recognize the conserved microbial structures and induce the first line of defence (Thompson et al. [@CR37]). PRRs also comprise the family of the Toll-like receptors (TLRs), which were first identified for their role in embryonic development in *Drosophila*, but subsequently appeared important elements of innate immunity in adult flies, with their homologs found across the evolutionary spectrum up to humans (Kawai and Akira [@CR15]). Considering data from other PRRs, it seemed plausible that TLRs, especially those sensing viral nucleic acids, might equally harbour susceptibility loci for autoimmune conditions. Indeed, variations within the *TLR3* locus (4q35) are associated with predisposition to viral infections and to systemic autoimmune diseases (Laska et al. [@CR18]; Qian et al. [@CR27]; Svensson et al. [@CR35]). TLR3 is an endosomal receptor, which recognizes double-stranded RNA (dsRNA), an intermediate during the replication of most viruses, and triggers immune responses by stimulating the synthesis of type I IFNs and inflammatory cytokines (Alexopoulou et al. [@CR1]). Not only is it expressed in a variety of immune cells, but also found in human and rodent pancreatic beta cells and adrenal cortex (Alexopoulou et al. [@CR1]; Hultcrantz et al. [@CR12]; Kanczkowski et al. [@CR14]). A study in a small South African cohort suggested an association between T1D and polymorphisms at the *TLR3* gene (Pirie et al. [@CR26]). This observation was further substantiated in a recent analysis of Brazilian population although T1D-associated single nucleotide polymorphisms (SNPs) did not overlap with the former African findings (Assmann et al. [@CR3]). On the contrary, data from the Han Chinese do not support the association between *TLR3* and T1D in Asians; however, only two gene variants were explored (Sun et al. [@CR34]). Polymorphisms of *TLR3* have not been analysed in AD and in European T1D cohorts to date. Our study was, therefore, designed to investigate the association of selected *TLR3* SNPs with these autoimmune endocrine disorders among Polish subjects.

Materials and Methods {#Sec2}
=====================

Two variants of the *TLR3* gene were genotyped in a cohort of 168 AD patients, 524 individuals with T1D and in 592 healthy controls issued from Caucasian Polish population. The diagnosis of T1D was based upon WHO criteria with an absolute dependence on exogenous insulin. Clinical diagnosis of adrenal failure was confirmed by either low basal serum cortisol with a high adrenocorticotropin level, or subnormal response to the short Synacthen test (Husebye et al. [@CR13]). Autoimmune aetiology was corroborated by positive serum autoantibodies to insulin, glutamic acid decarboxylase and/or islet antigen IA2 in T1D, and autoantibodies to 21-hydroxylase in AD. Mean age at AD onset was 32.6 (±10.9) years and mean age at T1D onset was 8.5 (±4.4) years. Patients were enrolled at the endocrine clinics of the Poznan University of Medical Sciences. Control subjects were recruited among healthy blood donors with negative history and no signs of autoimmune disorders. The local ethical board approved the study and informed consent was obtained from its participants.

Genomic DNA was extracted from the peripheral blood using Gentra Puregene Blood Kit (Qiagen, Hilden, Germany). Genotyping of rs13126816 and rs3775291 was performed by real-time PCR using commercial Taqman assays (C_32209947 and C_1731425_10). Allelic discrimination analyses were carried out using 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and Sds2.3 software. Genotypes were confirmed by direct DNA sequencing of both strands by BigDye Terminator Cycle Sequencing Ready Reaction Kit on ABI Prism 3730 Genetic Analyzer (Foster City, CA, USA) and controls were used in all genotyping reactions. To ensure fidelity, 8 % of samples were re-genotyped blind.

The study was designed as a replication of Brazilian findings in T1D, which revealed odds ratios (ORs) of 2.1 and 2.3 for rs13126816 and rs3775291, respectively. The power estimation, performed with PS Power and Sample Size calculator v.2.1.30 (Vanderbilt University, TN, USA) assuming an allelic OR of 1.5 and given the minor allele frequencies as observed in the control group, showed \>99 % power to detect effects of both studied SNPs in our T1D cohort and 87.8 and 89.9 % power to detect the respective effects of rs13126816 and rs3775291 in AD (*α* = 0.05).

Genotypes were checked for Hardy--Weinberg equilibrium (threshold *p* \> 0.05) using an online calculator available at the Helmholtz Center Munich website (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). *χ*^2^ test was used for association analysis on 2 × 2 and 2 × 3 contingency tables. Linkage disequilibrium (LD) measures, Lewontin's *D*′ and *r*^2^ coefficient, were calculated using Haploview v.4.1 (Broad Institute of Harvard and MIT, Cambridge, MA, USA). Haplotype frequencies were estimated based on maximum likelihood method and compared between patients and controls (*χ*^2^ test). Genotype-stratified normally distributed data on age at disease onset were compared using one-way ANOVA and those with non-normal distribution were analysed by Kruskal--Wallis test. Statistical calculations were performed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA).

Results {#Sec3}
=======

Both analysed polymorphisms were in Hardy--Weinberg equilibrium in all studied cohorts (*p* \> 0.150). The frequencies of alleles and genotypes of the two *TLR3* variants did not present significant differences between patients and controls (Table [1](#Tab1){ref-type="table"}).Table 1Distribution of the *TLR3* polymorphisms rs13126816 and rs3775291 in patients with Addison's disease (AD), type 1 diabetes (T1D) and healthy controls (CON)PolymorphismGenotypesAllelesAD\
*n* (%)T1D\
*n* (%)CON\
*n* (%)rs13126816GG104 (61.9)316 (60.3)345 (58.3)AG57 (33.9)181 (34.5)205 (34.6)AA7 (4.2)27 (5.2)42 (7.1)*p* = 0.359*p* = 0.389G265 (78.9)813 (77.6)895 (75.6)A71 (21.1)235 (22.4)289 (24.4)*p* value0.2120.269OR (95 % CI)0.829 (0.619--1.113)0.895 (0.735--1.090)rs3775291GG74 (44.1)253 (48.3)292 (49.3)AG76 (45.2)232 (44.3)236 (39.9)AA18 (10.7)39 (7.4)64 (10.8)*p* = 0.432*p* = 0.092G224 (66.7)738 (70.4)820 (69.3)A112 (33.3)310 (29.6)364 (30.7)*p* value0.3660.550OR (95 % CI)1.126 (0.870--1.458)0.946 (0.789--1.134)*p* values represent comparison between patients and controls*OR* odds ratio, *CI* confidence interval

Linkage disequilibrium evaluation revealed moderate LD between studied SNPs, with the *D*′ values ranging between 0.69 and 0.76 and the *r*^2^ values between 0.24 and 0.43 in investigated cohorts. The analysis of the inferred two-allele haplotypes demonstrated increased frequency of the rs13126816/G--rs3775291/A haplotype in AD subjects (*p* = 0.002) and a similar borderline trend among T1D patients (*p* = 0.055) compared to controls (Table [2](#Tab2){ref-type="table"}).Table 2Distribution of the *TLR3* bi-allelic haplotypes (rs13126816--rs3775291) in patients with Addison's disease (AD), type 1 diabetes (T1D) and healthy controls (CON)AD (2n = 336)*p* valueT1D (2n = 1048)*p* valueCON (2n = 1184)GG208 (61.9)Reference686 (65.4)Reference773 (65.3)AA58 (17.3)0.425178 (17.0)0.067246 (20.8)GA55 (16.4)0.002136 (13.0)0.055118 (10.0)AG15 (4.4)0.57748 (4.6)0.50747 (3.9)*p* values represent comparison between patients and controls (GG---reference haplotype)

No influence of the polymorphic *TLR3* variants on the age at disease diagnosis was detected in either AD or T1D cohort (*p* = 0.870 and *p* = 0.731 for comparisons between three rs13126816 genotypes and *p* = 0.636 and *p* = 0.074 for comparisons between three rs3775291 genotypes, respectively).

Discussion {#Sec4}
==========

Numerous data from the animal models treated with synthetic dsRNA analogue, polyinosinic--polycytidylic acid \[poly(I:C)\], support the hypothesis that disturbed TLR3 function may contribute to the development of T1D in susceptible individuals (Alkanani et al. [@CR2]; Devendra et al. [@CR7]; Moriyama et al. [@CR23]; Sobel et al. [@CR33]). Recent findings from mice, which present widespread apoptosis of the pancreatic cells in response to a rotavirus infection, indicate that the detrimental viral effect on the pancreas is initially mediated by the dsRNA--TLR3 interaction (Honeyman et al. [@CR10]). Furthermore, it has been demonstrated that virus-infected or IFN-stimulated human islets displayed increased TLR3 expression (Hultcrantz et al. [@CR12]; Sarmiento et al. [@CR28]). With respect to adrenal autoimmunity, TLR3-expressing adrenocortical carcinoma cells stimulated with poly(I:C) along with IFN-γ or tumor necrosis factor *α* display significant rise in production of CXCL10, a chemokine involved in autoimmune adrenal failure (Bratland et al. [@CR6]). These data suggest that TLR3 may be an important player in autoimmune endocrinopathy and its altered function could contribute to disease development. Unfortunately, the current study does not support an association between *TLR3* polymorphisms and autoimmune endocrine conditions in Polish patients. Despite slightly larger T1D and control cohorts, we were unable to replicate the Brazilian findings and we could not demonstrate an association of rs13126816 or rs3775291 with AD either. The power of the current study exceeded recommended 80 % when calculated for an OR of 1.5; however, it could still be insufficient to detect a smaller effect (Hong and Park [@CR11]).

The initial analysis of the *TLR3* region in T1D comprised several SNPs evaluated in a cohort of 79 South African patients. Significant associations were found for three variants: rs5743313, rs5743315 and 2690 A/G but none of them survived multiple-comparisons correction (Pirie et al. [@CR26]). In the subsequent Brazilian study, the choice of investigated polymorphisms was based on linkage disequilibrium pattern across *TLR3* region and previously known associations with various immune conditions (Assmann et al. [@CR3]). Two variants (rs13126816 and rs3775291) appeared significantly associated with T1D (Assmann et al. [@CR3]). Rs13126816 in the long intron 1 had been previously correlated with the expression of TLR3, clearance of hepatitis C virus, rubella virus-specific cytokine responses, and susceptibility to herpesvirus-2 infection (Ovsyannikova et al. [@CR24]; Qian et al. [@CR27]; Svensson et al. [@CR35]). The non-synonymous rs3775291 (Leu412Phe) located in exon 4 confers reduced binding capacity to dsRNA and is associated with susceptibility to viral infections and systemic autoimmunity (Barkhash et al. [@CR4]; Laska et al. [@CR18]; Sironi et al. [@CR30]; Svensson et al. [@CR35]). On the contrary, our study failed to detect any association of the rs13126816 and rs3775291 with the organ-specific autoimmune conditions. However, haplotype analysis suggests that combined allele effect might play a role. In line, the frequency of the disease in Brazilians appeared to rise with the overall number of the *TLR3* risk alleles. Nonetheless, the rs3775291 T1D risk allele from the Brazilian study was opposite to the one, which could plausibly contribute to AD susceptibility in our cohort and which is connected with systemic autoimmune conditions and resistance to viral infections (Laska et al. [@CR18]; McCartney et al. [@CR20]; Svensson et al. [@CR35]). Discrepant allele effects are not uncommon in case--control studies and usually explained on the basis of the population differences (Fichna et al. [@CR8]; Owen et al. [@CR25]). Considering multi-ethnic Brazilian society and the fact that study participants were only self-defined as white (Assmann et al. [@CR3]), population stratification might be implicated (Lander and Schork [@CR17]). Moreover, Brazilian control group displayed distinct allele frequencies compared to healthy subjects in other Caucasian populations, including our cohort (rs13126816/A found in 38 % Brazilians vs. 26.9 % in CEU HapMap sample, and rs3775291/A in 37 % Brazilian controls vs. 25.4--33.7 % in other Caucasians) (Assmann et al. [@CR3]; Kindberg et al. [@CR16]; Laska et al. [@CR18]; Sironi et al. [@CR30]). Finally, there might be another causative *TLR3* variant implicated in autoimmune endocrine conditions, and differences in LD pattern across various populations could contribute to discrepant results for rs13126816 and rs3775291. However, genuine lack of *TLR3* association with T1D is further underpinned by the results of the genome-wide scans in the large Caucasian cohorts, with the closest association localized to the interleukin-2 gene at 4q27 (Barrett et al. [@CR5]; Smyth et al. [@CR32]; Todd et al. [@CR38]; Wellcome Trust Case Control Consortium [@CR39]).

In conclusion, *TLR3* polymorphisms are not likely to be associated with the risk for T1D and AD in Polish population. However, considering increasing evidence of interference between innate immunity and self-aggressive phenomena, it may still be of interest to investigate a larger set of innate immunity genes in the autoimmune endocrine conditions in future.
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